Jerusalem, 29 June, 2025 (TPS-IL) — Israeli medical device company IceCure Medical has announced July 9, 2025, as the record date for its planned $10 million rights offering. Shareholders as of that date will be eligible to purchase new units—each consisting of one ordinary share and a warrant—at $1.00 per unit. The subscription period runs from July 10 to July 28. IceCure’s largest shareholder, Epoch Partner Investments, has committed up to $5 million.
Proceeds will repay a $2 million bridge loan from Epoch and support general operations.
IceCure develops cryoablation systems for non-surgical tumor treatment, with its flagship ProSense system used worldwide.